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Abstract HER2/neu is known to be overexpressed in approxi-
mately 40% of human breast and ovarian cancers and it is
associated with increased metastasis and poor prognosis. We
have shown previously that the N-terminal domain of simian
virus 40 large T antigen (LT425) can act as a transforming
suppressor of the HER2/neu oncogene in human ovarian cancer.
In the present study, we demonstrate that LT425 can also repress
the transforming properties of HER2/neu-overexpressing human
breast cancer cells. In addition, the results of a chemotaxis assay
and an in vitro chemoinvasion assay further suggest that LT425
can also suppress the metastatic potential of the HER2/neu-
transformed breast cancer cells. Taken together, these data
clearly suggest that the inhibition of the expression of
p185HER2=neu tyrosine kinase by LT425 is capable of suppressing
the HER2/neu-mediated transformation and metastatic potential
in breast cancers. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The HER2/neu protooncogene encodes a 185 kDa trans-
membrane glycoprotein (p185HER2=neu) with intrinsic tyrosine
kinase activity and belongs to the epidermal growth factor
receptor family of four closely related receptors, termed
HER1 (EGFR), HER2 (c-erbB-2; neu), HER3 and HER4
[1^5]. Ampli¢cation of the HER2/neu gene and overexpression
of its product induce cell transformation. Extensive studies
have reported that HER2/neu is overexpressed in 30^50% of
human breast tumors [6^8]. Breast tumors are the most com-
mon form of malignancy found among women, but in addi-
tion to breast carcinomas, a wide variety of other human
cancers are also frequently found to demonstrate ampli¢ca-
tion or overexpression of HER2/neu, including ovarian, gas-
tric, head and neck, colon, lung, oral, cervical, and prostatic
cancers [9,10]. In the past decade, it has shown that the am-
pli¢cation/overexpression of the HER2/neu gene was corre-
lated with malignant phenomena in breast cancers, such as
enhanced malignancy of the tumor, a shorter time to relapse,
shorter post-relapse survival, more therapeutic resistance, and
decreased overall survival rate [11]. In addition, experiments
using transgenic mice indicated that introduction of the mouse
HER2/neu gene into mice can induce mammary tumors and
metastases [12], while overexpression of the HER2/neu gene
enhances the intrinsic metastatic potential in human breast
cancer cells by increasing invasion ability [13]. It appears,
therefore, that HER2/neu overexpression plays an important
role in human breast cancer development and metastasis and
it is a promising target for the development of cancer thera-
pies.
Several oncogene products, such as the adenovirus 5 (Ad5)
E1A, c-Myc, c-Cbl, and PEA3 gene products and the simian
virus 40 large T antigen (SV40LT) have been demonstrated to
act as repressors of the HER2/neu oncogene [14^19,37]. The
repression mechanisms of Ad5 E1A, c-Myc, c-Cbl and PEA3
have all been reported [15,18,21,37], but the exact molecular
mechanism for the suppression of HER2/neu gene expression
by SV40LT remains unclear. SV40LT is the major oncopro-
tein of the DNA tumor virus SV40. It is a multifunctional
nuclear phosphoprotein and is required for the transformation
and DNA replication of the virus [22^26,38^40]. It also plays
a critical role in the deregulation of cellular proliferation and
thus there are oncogenic concerns regarding it as a therapeutic
agent. Fortunately, as we have shown in a previously study
[17], when only the N-terminal domain of SV40LT (designed
LT425) is used, the transforming potential of the wild type
SV40LT is eliminate while its suppressing activity on HER2/
neu overexpression in human ovarian cancer cells is still re-
tained, meaning that LT425 is suitable for clinical applications
in human cancer gene therapy. We also demonstrated that the
enforced expression of LT425 can signi¢cantly retard the cell
growth and tumorigenicity of ovarian cancer cells in vitro [17].
However, prior to the present study, it was still not known
whether LT425 could also inhibit human breast cancer cell
growth and suppress the transformation phenotype and meta-
static potential of HER2/neu-overexpressing breast cancers. In
this report, we show that expression of LT425 not only de-
creases the growth rate and reduces soft-agarose colony-form-
ing ability, but also inhibits the metastasis-associated proper-
ties of human breast cancer cells. Thus, in addition to its
function as a tumor suppressor of HER2/neu, LT425 may
also be a metastasis suppressor of HER2/neu. Our results
demonstrate that LT425 is capable of down-regulating the
HER2/neu-mediated metastatic potential, suggesting that
LT425 may have therapeutic potential for HER2/neu-induced
metastasis.
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2. Material and methods
2.1. Construction of LT425-expressing plasmid and cell culture
The LT425-expressing and its frame-shift mutant plasmids were
constructed by inserting the LT425 gene into the HindIII/XhoI site
of the pCMV-Tag 2A and 2B vectors (Stratagene Cloning System,
USA), resulting in pCMV-Flag-LT425 and pCMV-Flag-LT425-M
plasmids, respectively. A termination codon was generated right after
the translation initiation codon of aLT425 due to an ‘A’ insertion
after the Flag sequence. Thus, no LT425 peptide was formed from
the plasmid pCMV-Flag-LT425-M. MDA-MB-453, a human breast
cancer cell line expressing high levels of HER2/neu, was kindly pro-
vided by Dr. Hung MC (University of Texas M.D. Anderson Cancer
Center, Houston, TX, USA) and cultured in L-15 (Life Technologies,
Inc., USA) medium supplemented with 10% (v/v) fetal bovine serum
(FBS). Cells were transfected with pCMV-Flag-LT425 or pCMV-
Flag-LT425-M using Lipofectamine plus reagent (Life Technologies,
Inc.) and selected in 600 Wg/ml of G418 (geneticin; Life Technologies,
Inc.). Stable lines were cultured under the same conditions as the
parental line with the addition of G418 (500 Wg/ml) selection reagent
(Life Technologies, Inc., USA).
2.2. Western blot analysis
Cell lysates were prepared and sedimented as described previously
[17]. The supernatant was used for SDS^PAGE analysis. 80 Wg of
each cell sample were loaded onto the NuPAGE1 4^12% Bis^Tris
Gel (NP0322, Invitrogen, USA). After electrophoresis, the gel was
blotted onto nitrocellulose ¢lter membranes. The ¢lter membranes
were subjected to blocking with 5% skim milk in TBST bu¡er (10
mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 h at room
temperature. The membranes were then incubated with the primary
anti-neu antibody (Ab-3; 1:1000 dilution; Oncogene Science, NY,
USA), anti-FLAG antibody (anti-FLAG M2; 1:1000 dilution; Stra-
tagene) or anti-L-actin monoclonal antibody (1:5000 dilution) in fresh
TBST bu¡er for 1 h at room temperature, followed by washing and
incubation with the secondary antibody of goat anti-mouse IgG Fc-
HRP (1:2000 dilution; Amersham). Visualization was by an Amer-
sham ECL chemiluminescence system.
2.3. Cell growth rate assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) metabolic assay was performed as described by Loveland et al.
[27]. In brief, the cells were seeded at a density of 3U103 cells into
microtiter plates and incubated in 200 Wl medium supplemented either
with 10% or 0.1% FBS. At ¢ve 24-h intervals, viable cells were reacted
with 20 Wl MTT (5 mg/ml in phosphate-bu¡ered saline (PBS); Sigma
Chemical Co.) for 4^6 h at 37‡C. Then, 170 Wl of the remainder,
which contained the MTT^formazan crystals, was dissolved in 200
Wl dimethyl sulfoxide. Finally, the absorbance was measured at 545
nm.
2.4. Anchorage independence assay
For the soft-agarose growth assay used in this study, the wild type
and mutant LT425 lines and their parental MDA-MB-453 cells
(5U103 cells/well) were plated in 24-well plates in culture medium
containing 0.35% agarose (Gibco-BRL, Gaithersburg, MD, USA)
overlying a 0.7% agarose layer. The cells were then incubated at
37‡C for 4 weeks, after which the plates were stained with p-iodoni-
trotetrazolium violet (1 mg/ml) overnight at 37‡C. Colonies greater
than 100 Wm in diameter were counted for each dish. Each soft-aga-
rose assay was performed in triplicate.
2.5. Chemotaxis assay
The chemotaxis assays were performed by using a transwell unit
with an 8 Wm pore size polycarbonate ¢lter in a 24-well cluster plate
(Costar, Cat. 3422), as described in Yu et al. [20] with slight modi¢-
cations. Each lower compartment of the transwell contained 600 Wl of
MDA-MB-453 parental or LT425 transfected cell-conditioned me-
dium or serum-free medium alone (as negative control). The condi-
tioned medium was prepared from culturing cells in L-15/0.1% BSA
without serum for 3 days. After harvesting cells by trypsinization, the
cells were then suspended in L-15 containing 10% FBS to inactivate
the enzyme, and then centrifuged and resuspended in L-15 serum-free
medium. Cells (5U104/0.1 ml of L-15 medium) were placed in the
upper compartment of the transwell unit and incubated for 6 h at
37‡C in a humidi¢ed 5% CO2 atmosphere. After incubation, ¢lters
were ¢xed with 3% glutaraldehyde in PBS for 2 h and then stained
with 10% Giemsa for 1 h. After washing with PBS, the cells on the
upper surface of the ¢lter were removed by wiping with a cotton
swab. Chemotactic activity was measured by counting the number
of cells that had migrated to the lower side of the ¢lter with a Nikon
microscope (Coolpix 990) at 200U magni¢cation.
2.6. In vitro chemoinvasion assay
To perform the in vitro invasiveness assay, we followed the meth-
ods described by Albini et al. [28], Repesh [29] and Yu et al. [20] with
minor modi¢cations. Matrigel was used as the basement membrane
and purchased from Becton Dickinson Labware (MA, USA). Each
¢lter in the transwell unit (the same as used in the chemotaxis assay)
was coated with 0.1 ml of 1:60 dilution (21 Wg/well) of Matrigel in
cold L-15 serum-free medium to form a thin, continuous barrier on
the top of the upper ¢lter. The Matrigel was left to air-dry overnight
and was reconstituted with 0.15 ml of L-15 serum-free medium at
room temperature for 3 h. The lower compartment contained 0.6 ml
of conditioned medium (the same as in the chemotaxis assay) as
chemoattractant or L-15 medium as negative control. After removing
the excess medium, each type of cell (5U104/0.1 ml in L-15 medium)
was added on the top of the Matrigel layer, and incubated for 3 days
at 37‡C in a humidi¢ed 5% CO2 atmosphere. Cells were ¢xed, stained
and counted as described for the chemotaxis assay.
3. Results
3.1. Down-regulation of HER2/neu overexpression in breast
cancer cells by LT425
To determine whether LT425 could down-regulate HER2/
neu overexpression, the MDA-MB-453 human breast cancer
cells were either stably transfected with LT425 cDNA (con-
sisting of the N-terminal 178 amino acid residues of SV40LT;
Fig. 1. Western blot analysis of the LT425-expressing MDA-MB-
453 stable transfectants. A: Stable integration and expression of
LT425 in MDA-MB-453 cells reduced p185 levels. All of the 453-
LT425 transfectants had lower p185 expression than the frame-shift
mutants (453-LT425-M) and the parental MDA-MB-453 cells. B:
Comparison of the two LT425-expressing stable transfectants, 453-
LT425-1.3 and -1.6, and one mutant, 453-LT453-M3, that were
used in this study. The primary antibodies used in this Western blot
experiment were anti-neu (upper), anti-Flag (middle), and anti-L-ac-
tin (lower) antibodies, respectively.
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the resultant cell lines are referred to as 453-LT425 transfec-
tants) or its frame-shift mutant and then the p185HER2=neu
expression levels were compared. As shown in Fig. 1A, all
of the LT425-expressing lines had signi¢cantly reduced
HER2/neu levels compared with the parental and mutant
lines. In addition, the results from the densitometric analysis
suggested that HER2/neu expression in the two LT425 trans-
fected stable lines used in this study, 453-LT425-1.3 and -1.6,
were dramatically lower than those in the parental line and in
the 453-LT425-M3 mutant control line (Fig. 1B). The expres-
sion of LT425 in the two LT425-transfected stable lines, 453-
LT425-1.3 and -1.6, but not in the parental 453 and mutant
453-LT425-M3 lines, was further identi¢ed by anti-Flag anti-
body (middle panel of Fig. 1B).
3.2. E¡ect of LT425 expression on cell growth in vitro
To examine the e¡ect of LT425 expression on the trans-
forming ability of HER2/neu-overexpressing human breast
MDA-MB-453 cells, we assayed the two 453-LT425 transfec-
tants, 453-LT425-1.3 and -1.6, as well as the control MDA-
MB-453 (parental) and 453-LT425-M3 (mutant) lines for the
known transforming parameters. Using the MTT metabolic
analysis, a markedly reduced growth rate was observed in
LT425-expressing MDA-MB-453 lines (Fig. 2B) in serum-
free (0.1% FBS) medium compared to the parental 453 and
mutant 453-LT425-M3 lines. These results showed that ex-
pression of LT425 resulted in a decrease in the cell-doubling
time compared with the control and frame-shift cell lines.
Fig. 2. Growth rate analysis of parental and LT425 stably trans-
fected MDA-MB-453 cells. Cells were plated in 96-well microtiter
plates (3U103 cells/well) and incubated for up to 5 days. At 24-h in-
tervals, relative cell numbers were determined using the MTT meta-
bolic assay. Mean values from six replicate wells were plotted
against time in culture. A: 10% FBS/L-15 medium; B: serum-free
(0.1% FBS) L-15 medium.
Fig. 3. LT425 inhibits the transformation phenotype of breast can-
cer cells. A: Soft-agarose assay of MDA-MB-453, 453-LT425-M3,
453-LT425-1.3, and 453-LT425-1.6 cell lines. All cells (5U103 cells/
well) were subjected to anchorage-independent growth in 0.35% soft
agarose for 4 weeks. B: Number of colonies formed in soft agarose
as shown in (A).
Fig. 4. Inhibition of HER2/neu-transformed MDA-MB-453 cells
motility by LT425 gene products. MDA-MB-453, 453-LT425-M3,
453-LT425-1.3, and 453-LT425-1.6 cell lines were assayed for che-
motactic activity. Migrated cells were counted in three random ¢elds
(200U magni¢cation). All assays were performed in triplicate, and
assays were repeated twice.
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3.3. LT425 expression can inhibit the anchorage-independent
growth of human breast cancer cells
Anchorage-independent growth in semi-solid agarose is one
of the indicators of transforming ability for transformed cells.
To test the e¡ect of the LT425 protein expression in breast
cancer cells on anchorage-independent growth, we assayed the
parental MDA-MB-453 cells, the frame-shift mutant 453-
LT425-M3 and the two LT425 transfectant lines, 453-
LT425-1.3 and -1.6, for their ability to grow in soft agarose.
As shown in Fig. 3, HER-2/neu-overexpressing MDA-MB-
453 human breast cancer cells and the mutant line were
more e⁄cient in forming soft-agarose colonies. In contrast,
the colony-forming ability of the LT425-expressing lines was
dramatically reduced, suggesting that LT425 expression in the
MDA-MB-453 cells decreases the anchorage-independent
growth ability of these tumor cells.
3.4. Abrogation of metastatic properties of HER2/neu-
transformed cells by LT425
In the tumor-cell metastasis process, malignant cells must
extravasate from the circulation, invade basement membrane
and colonize distant sites. The metastatic phenotype involves
multiple cellular events that may vary across species, and tu-
mor-cell migration and invasion can serve as important indi-
cators of these events. HER2/neu is likely to be involved in
these processes, particularly in HER2/neu-positive breast tu-
mors, in which HER2/neu-transformed tumor cells are re-
ported to have higher chemotactic activities than HER2/neu
negative ones [20,41]. To examine whether LT425 can inhibit
chemotaxis of the HER2/neu-transformed breast cancer cells,
we therefore measured the migration of 453-LT425-1.3, -1.6,
-M3 and parental MDA-MB-453 cells towards a chemoattrac-
tant (cell-conditioned medium). As shown in Fig. 4, the pa-
rental and mutant lines had higher migration rates, whereas
the two LT425-transfected lines showed lower chemotactic
activity. These results suggest that expression of LT425 in
HER2/neu-transformed cells inhibits chemotaxis in these
HER2/neu-overexpressing breast cancer cells.
In addition, an in vitro invasion assays was used to com-
pare the invasiveness of 453-LT425-1.3, -1.6, -M3 and paren-
tal MDA-MB-453 to determine whether LT425 can be used to
diminish the invasive properties of HER2/neu-transformed
breast cancer cells. A layer of reconstituted basement mem-
brane (Matrigel) was used on the surface of a transwell insert
¢lter as the invasion substrate, with the cell-conditioned me-
dium placed in the lower chamber beneath the ¢lter to stim-
ulate penetration of the cells. The assay revealed marked dif-
ferences in invasiveness between the LT425-transfectant lines
and control lines. Both the 453-LT425-1.3 and -1.6 lines
showed very low rates of invasion, whereas the parental and
mutant lines showed dramatically higher abilities to invade
the Matrigel layer (Fig. 5), suggesting that LT425 can inhibit
the invasive ability of the HER2/neu-overexpressing MDA-
MB-453 cells in vitro.
4. Discussion
The wild type SV40LT is known to a¡ect the proliferation
of HER2/neu-overexpressing cancer cell types by negatively
regulating the HER2/neu promoter activity. In a previous
paper, we showed that the N-terminal domain only of the
SV40LT (LT425) can inhibit the expression of the HER2/
neu oncogene at the transcriptional level and reduce the tu-
morigenicity of HER2/neu-transformed ovarian cancer cells
[17]. In the present study, we demonstrate that the LT425
can act as a transforming suppressor of the HER2/neu-over-
expressing human breast cancer cells by down-regulating the
endogenous p185HER2=neu level and repressing the transforma-
tion properties of HER-2/neu-overexpressing breast cancer
cells in vitro (Fig. 1^3).
It does not necessarily follow, however, that metastasis will
likewise be suppressed by LT425 because although metastasis
and transformation are related phenomena, they are also sep-
arable, and it has been suggested that they may be regulated
by di¡erent molecular mechanisms [30,31]. Of itself, breast
cancer metastasis represents a serious challenge to therapeutic
intervention. In HER2/neu-positive breast cancer patients
there is a high correlation with lymph node metastasis, and
metastasis is the major cause of death for these patients [6,32^
34]. The entire process of tumor cell metastasis and invasion
consists of: secretion of hydrolytic enzymes to the locally
degraded matrix, penetration across the basement membrane
into the blood circulation, spread and adhesion to the endo-
thelia, sequential penetration backward across the basement
membrane, attachment to the matrix, secretion of hydrolytic
enzymes to the invaded matrix, and locomotion into the re-
gion of the stroma [20,35,36]. Within this complex sequence of
Fig. 5. Inhibition of invasion of HER2/neu-transformed MDA-MB-
453 cells through a Matrigel layer by LT425 gene products. A: The
lower surface of the ¢lter from the transwell unit at the end of the
chemoinvasion activity assay. B: The Matrigel-invaded cells were
counted in three random ¢elds (200U magni¢cation). All assays
were performed in duplicate, and triplicate experiments were run for
each cell line.
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events, both cell motility enhancement and tissue invasiveness
are the two key steps for the metastatic phenotypes, and in
this study, it was shown that both these two metastatic steps
are inhibited by the expression of LT425 in the HER2/neu-
overexpressing human breast cancer cells (Figs. 4 and 5).
These results thus suggest that LT425 may also act as an
e¡ective suppressor of breast cancer metastasis.
The results of this study raise two questions. First, whether
suppression of the metastatic potential of HER2/neu-overex-
pressing breast cancer cells by LT425 is dependent upon or
independent of repression of HER2/neu gene expression. To
clarify this issue, an irrelevant promoter, such as the RSV
promoter (which cannot be regulated by LT425), should be
used to drive the HER2/neu cDNA and expressed in the
MDA-MB-453 breast cancer lines stably transfected with
LT425. Comparison of the metastasis-associated properties
between these cell lines and their parental lines should then
reveal which of the possible molecular mechanisms is used by
LT425 in its repression of metastasis. The second question is
whether LT425 suppresses the metastatic potential of MDA-
MB-453 breast cancer cells by decreasing the growth rate of
these cells. As shown in Fig. 2A, there is not much di¡erence
among the growth curves of the parental MDA-MB-453 cells,
the 453-LT425 transfectants, and the 453-M3 mutant line in
complete medium. This suggests that LT425 can repress the
intrinsic metastatic potential of MDA-MB-453 breast cancer
cells without reducing their growth rates, indicating that sup-
pression of the HER2/neu-mediated metastasis by LT425 may
be through a di¡erent molecular mechanism. In conclusion,
our results demonstrate that LT425 can act as both transfor-
mation and metastasis suppressor of these human breast can-
cer cells, suggesting a possible therapeutic bene¢t in cases of
clinical breast cancer.
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